Literature DB >> 2872929

Covalent crosslinking of von Willebrand factor to fibrin.

M Hada, M Kaminski, P Bockenstedt, J McDonagh.   

Abstract

Factor XIIIa crosslinks a limited number of substrates via epsilon(gamma-glutamyl)-lysyl bond formation. It crosslinks fibrin to itself, alpha 2-plasmin inhibitor and fibronectin to fibrin, and fibronectin to collagen. Results presented here show that plasma von Willebrand factor (vWF) is a substrate for factor XIIIa and can be crosslinked to fibrin during gel formation. vWF-fibrin crosslinking was studied in purified systems and in plasma with 125I-vWF and 131I-fibrinogen. vWF incorporation into fibrin increased with time or increasing factor XIIIa. After electrophoresis of dissolved clots, distribution of 125I and 131I was measured and showed that vWF was crosslinked to the alpha chain of fibrin and entered the high-mol-wt alpha polymer. vWF-fibrin crosslinking decreased the initial rate of alpha polymer formation. Crosslinking of vWF polymer to itself could not be demonstrated under physiologic conditions but occurred if vWF was reduced first. Factor XIIIa catalyzed incorporation of putrescine into both monomeric and polymeric vWF. Altogether, these studies indicate that factor XIIIa can readily form covalent bonds between glutamine in vWF and lysine in fibrin alpha chains. This reaction occurs readily in vitro when plasma clotting is slow and may occur in vivo under similar conditions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872929

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Post-translational modification of apolipoprotein B by transglutaminases.

Authors:  E Cocuzzi; M Piacentini; S Beninati; S I Chung
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

2.  Thrombin-dependent Incorporation of von Willebrand Factor into a Fibrin Network.

Authors:  Adam Miszta; Leonie Pelkmans; Theo Lindhout; Ganeshram Krishnamoorthy; Philip G de Groot; Coenraad H Hemker; Johan W M Heemskerk; Hilde Kelchtermans; Bas de Laat
Journal:  J Biol Chem       Date:  2014-11-07       Impact factor: 5.157

3.  Coagulation factor XIIIa substrates in human plasma: identification and incorporation into the clot.

Authors:  Camilla Lund Nikolajsen; Thomas F Dyrlund; Ebbe Toftgaard Poulsen; Jan J Enghild; Carsten Scavenius
Journal:  J Biol Chem       Date:  2014-01-17       Impact factor: 5.157

4.  Rapid formation of large molecular weight alpha-polymers in cross-linked fibrin induced by high factor XIII concentrations. Role of platelet factor XIII.

Authors:  C W Francis; V J Marder
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

5.  Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII.

Authors:  V C Yee; L C Pedersen; I Le Trong; P D Bishop; R E Stenkamp; D C Teller
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

Review 6.  Peptide-based topical agents and intravenous hemostat for rapid hemostasis.

Authors:  Snehasish Ghosh; Archana Tripathi; Paramita Gayen; Rituparna Sinha Roy
Journal:  RSC Med Chem       Date:  2020-10-08

7.  Fibrin-based 3D matrices induce angiogenic behavior of adipose-derived stem cells.

Authors:  Eunna Chung; Julie A Rytlewski; Arjun G Merchant; Kabir S Dhada; Evan W Lewis; Laura J Suggs
Journal:  Acta Biomater       Date:  2015-01-16       Impact factor: 8.947

8.  Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells.

Authors:  T A Brock; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

Review 9.  Platelet adhesion under flow.

Authors:  Zaverio M Ruggeri
Journal:  Microcirculation       Date:  2009-01       Impact factor: 2.628

10.  Adaptor SH3BGRL promotes breast cancer metastasis through PFN1 degradation by translational STUB1 upregulation.

Authors:  Shaoyang Zhang; Xuemin Guo; Xiufeng Liu; Zhixiong Zhong; Shulan Yang; Haihe Wang
Journal:  Oncogene       Date:  2021-07-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.